BEAM

BEAM INC COM STK (DE)

BEAM

Overview Fund Trends Analyst Outlook Journalist POV

Delisted

BEAM was delisted on the 30th of April, 2014.

Back to rankings

Positive

Neutral

Negative

Sentiment 3-Months

Positive

Neutral 54.5%

Negative

Schaeffers Research

Top Stock Pick Report: A Q3 For the Record Books

Subscribers to Chart of the Week received this commentary on Sunday, October 5.

Top Stock Pick Report: A Q3 For the Record Books

Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Beam Therapeutics Inc. (NASDAQ:BEAM ) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 10:30 AM EDT Company Participants John Evans - CEO & Director Conference Call Participants Patrick Trucchio - H.C.

Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript

Beam Therapeutics Inc. (NASDAQ:BEAM ) Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants John Evans - CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President All right. Good afternoon.

Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript

Zacks Investment Research

CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?

CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.

CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m.

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Zacks Investment Research

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

Zacks Investment Research

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.11 per share a year ago.

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

See News Rankings